[ad_1]
Garden City, New York-based ProPhase recently announced a Memorandum of Understanding (MOU) between its ProPhase Precision Medicine Inc. and Nebula Genomics subsidiaries and Persian Gulf Emirate-based G42 Healthcare.
Using genomic data
The MoU covers genome sequencing, artificial intelligence, sharing of genomic data insights. The companies also have an initial plan to “synergy” their respective genome-sequencing capabilities.
G42 Healthcare is part of an Abu Dhabi company called Group 42 (G42), which describes itself as “a leading artificial intelligence and cloud computing company developing and implementing holistic and scalable artificial intelligence solutions. ”
The company has reportedly launched a $10 billion fund to invest in late-stage technology companies. Xiao Peng, CEO of G42, was educated in Hawaii and Washington, D.C., and sits on the board of Yahsat, a satellite communications company headquartered in the United Arab Emirates.
“G42 Healthcare is the enabler of the world’s largest and most comprehensive population genomics programme – the UAE Genome Project, which aims to transform traditional ecosystems from disease care to preventive healthcare for UAE citizens, making G42 Healthcare ProPhase ideal strategic relationship as we look to strengthen our next-generation sequencing capabilities and build our new state-of-the-art genome sequencing facility,”said Ted Karkus, CEO of ProPhase Lab.
Dr. George Church, professor of genetics at Harvard Medical School and founder of Nebula Genomics, said, “As an active advisor to ProPhase Labs and G42, I am delighted that this collaboration brings together two organizations that are leaders in next-generation sequencing.”
In addition to a diagnostic laboratory for rapid COVID-19 testing, ProPhase Labs operates a dietary supplement contract manufacturing facility and distributes the TK line of supplements for men’s sexual and prostate health.
[ad_2]
Source link
